AWARD WINNING PRESENTATION at ESCCA 2023
Download the full presentation Our own CTO, Lei Chen, held an award winning presentation at ESCCA 2023 in Utrecht, “Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay”. In the presentation you can see results of testing AML patients using FCM, NGS, ddPCR and Rarity Biosciences ultra-sensitive superRCA. The presentation also suggests why Flow-MRD and superRCA molecular-MRD […]
Rarity Bioscience nominated for ESCCA Best Abstract Award
Read the full abstract here We are thrilled to share that Rarity Bioscience together with Karolinska Institutet and Uppsala University are nominated to the ESCCA Best Abstract Award, for the abstract “Ultra-sensitive molecular MRD on flow cytometer using superRCA mutation assay.”. A spart of that we have been awarded a plenary session presentation. Come and […]
Multiplex KRAS superRCA assays
Rarity offers ultra-sensitive and multiplexed mutation detection on 21 of the most common KRAS hotspot mutations for liquid biopsy research. To see our Multiplex KRAS superRCA assays, and explore all our assays: Explore assays Analyzing KRAS mutations in cancer is crucial for understanding the underlying mechanisms of tumor growth. These mutations, prevalent in cancers like […]
Rarity Bioscience Achieves ISO 13485 Quality System Certification
We can now proudly announce that Rarity Bioscience have achieved the ISO 13485:2016 certification from BSI! The achievement emphasizes Rarity Bioscience’s commitment to becoming a trusted and reliable partner in research, diagnostics, and therapeutics. Attaining this certification sets Rarity Bioscience apart from other early stage biotech startups in the rapidly evolving field of diagnostics. “This certification […]
SciLifeLab Industry case: Rarity Bioscience enables precision medicine with superRCA technique
Industry case by SciLifeLab: Rarity Bioscience and SciLifeLab are collaborating to advance superRCA, a powerful tool for nucleic acid detection. The technique, initially a Technology Development Project at SciLifeLab, improves existing genetic technologies to enhance precision in identifying cancer mutations. Using expertise and equipment available at SciLifeLab Clinical Genomics, Rarity Bioscience can retrospectively test superRCA, a […]
New perspective article on Liquid Biopsy using superRCA
New perspective article on Liquid Biopsy using superRCA, from Uppsala University and Karolinska Institute: This perspective article compares existing techniques and the benefits and drawbacks of various types of assays for different applications, and their utility for diagnosis and monitoring. The authors discuss molecular methods for monitoring malignancies, particularly leukemias, and compare them to the […]
New chairperson of the board brings cutting-edge expertise
Per Matsson, an esteemed biotechnology leader, has been appointed as the new chairman of the Board at Rarity Bioscience. His appointment signifies Rarity Bioscience’s commitment to strong leadership and innovation in the biotech sector. Per Matsson is also one of the Co-founders of Rarity Bioscience. Per Matsson has over 30 years of life science experience, […]
New poster presented at International Symposium on Minimal Residual Cancer conference
CEO Linus Bosaeus, CTO Lei Chen and Dir. BD Alexander Kele attended the ISMRC (International Symposium on Minimal Residual Cancer) Conference in Hamburg, germany, 2023, to discuss topics such as precision diagnostics, liquid biopsies and treatment monitoring and present a new poster. The poster demonstrates initial data from a pilot study looking at the utility of cfDNA mutation […]
MRD poster presented at international AML conference
CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen attended the AML Conference in Munich, Germany 2023, to engage and discuss the main topics of this year such as novel target therapies and markers for Diagnosis and Prognosis. Linus Bosaeus and Lei Chen are there Monday til Wednesday and present poster #79, demonstrating positive […]
New assay available in our product portfolio
Using the superRCA technology, you can essentially detect any known sequence of interest using target specific ligation templates and padlock probes. The assay work on purified DNA coming from various types of samples, including cfDNA from liquid biopsies. Targets may be hotspot mutations, private driver mutations, or simply any sequence of interest. We now have […]